WFM
ACAD icon

Wilmington Funds Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Wilmington Funds Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$283K Sell
12,537
-4,230
-25% -$88.3K 0.03% 550
2014
Q1 		$408K Sell
16,767
-9,976
-37% -$252K 0.04% 425
2013
Q4 		$668K Buy
26,743
+363
+1% +$8.56K 0.07% 320
2013
Q3 		$725K Buy
+26,380
New +$551K 0.07% 285

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wilmington Funds Management's ACAD Position: Q2 2014 in Review

Wilmington Funds Management reduced its Acadia Pharmaceuticals (ACAD) stake by 25% in Q2 2014, selling an estimated $88.3K and leaving 12,537 shares worth $283K. The position accounts for 0.03% of the portfolio, ranked #550.

Wilmington Funds Management first reported a position in ACAD in Q3 2013 and has held it in 4 quarters since. The position peaked at $725K in Q3 2013. 160 funds tracked by Wall St. Rank hold ACAD as of Q2 2014.

  • Wilmington Funds Management held 12,537 shares of Acadia Pharmaceuticals worth $283K as of Q2 2014.
  • Wilmington Funds Management sold 4,230 Acadia Pharmaceuticals shares in Q2 2014, an estimated $88.3K.
  • Acadia Pharmaceuticals made up 0.03% of Wilmington Funds Management's portfolio in Q2 2014, its #550 holding.
  • Wilmington Funds Management first reported a position in Acadia Pharmaceuticals in Q3 2013 and has held it in 4 quarters since.
  • Wilmington Funds Management's Acadia Pharmaceuticals position peaked at $725K in Q3 2013.
  • 160 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.